Target Name: RTF1
NCBI ID: G23168
Review Report on RTF1 Target / Biomarker Content of Review Report on RTF1 Target / Biomarker
RTF1
Other Name(s): Ortholog of mouse gene trap locus 7 | GTL7 | RTF1 homolog, Paf1/RNA polymerase II complex component | Rtf1, Paf1/RNA polymerase II complex component, homolog | RTF1_HUMAN | CDG1N | RNA polymerase-associated protein RTF1 homolog | ortholog of mouse gene trap locus 7 | KIAA0252

Targeting RTF1: A Promising Approach To Drug Development

RTF1 (Ortholog of mouse gene trap locus 7) is a gene that has been identified as a potential drug target or biomarker in the field of genetics. RTF1 is a non-coding RNA molecule that is located on chromosome 6 and has been shown to play a role in the regulation of gene expression.

The Importance of RTF1

RTF1 is a critical regulator of gene expression in the mouse genome. It has been shown to play a role in the regulation of stem cell proliferation, differentiation, and plasticity. RTF1 has also been shown to be involved in the regulation of cell survival and death, as well as the regulation of inflammation.

One of the key functions of RTF1 is its role in the regulation of stem cell proliferation. Stem cells are a type of cell that have the ability to develop into any type of cell in the body. They are a key regulator of tissue repair and regeneration, and they have the potential to be used to treat a wide range of diseases.

RTF1 has been shown to play a critical role in the regulation of stem cell proliferation by regulating the expression of genes that are involved in cell growth and differentiation. It has been shown to inhibit the activity of the transcription factor, SMAD, which is involved in the regulation of stem cell proliferation.

Another function of RTF1 is its role in the regulation of cell death. When a cell is no longer needed, it can undergo a process of programmed cell death, known as apoptosis. RTF1 has been shown to play a role in the regulation of apoptosis in the body, and it has been shown to be involved in the regulation of stress responses and inflammation.

RTF1 has also been shown to play a role in the regulation of inflammation. Inflammation is a critical response of the immune system to injury or infection, and it can lead to a wide range of diseases. RTF1 has been shown to play a role in the regulation of inflammation by regulating the expression of genes that are involved in the immune response.

The Potential for Drug Targeting

The potential for drug targeting of RTF1 is significant. RTF1 has been shown to play a critical role in the regulation of stem cell proliferation, differentiation, and plasticity, as well as the regulation of cell survival and death, and the regulation of inflammation. These functions make it an attractive target for drugs that are aimed at treating a wide range of diseases.

One of the key challenges in drug targeting of RTF1 is the fact that it is a non-coding RNA molecule. This means that it is not possible to use traditional methods of drug targeting, such as genetic engineering or protein manipulation, to target RTF1 directly. Instead, drugs must be found that interact with RTF1 in a way that is beneficial for the treatment of disease.

One approach that has been shown to be effective in targeting RTF1 is the use of small molecules. Small molecules are a type of drug that can be used to inhibit the activity of RTF1, or to stimulate its activity in a way that is beneficial for the treatment of disease.

Several small molecules have been shown to interact with RTF1 and to be potential drug targets. For example, one small molecule, called S100, has been shown to inhibit the activity of RTF1 and to be beneficial for the treatment of cancer. Another small molecule, called R1, has been shown to stimulate the activity of RTF1 and to be beneficial for the treatment of neurodegenerative diseases.

Another approach that has been shown to be effective in targeting RTF1 is the use of antibodies. Antibodies are a type of protein that can be used to target specific molecules in the body, and they have been shown to be effective in targeting RTF1.

One

Protein Name: RTF1 Homolog, Paf1/RNA Polymerase II Complex Component

Functions: Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Binds single-stranded DNA. Required for maximal induction of heat-shock genes. Required for the trimethylation of histone H3 'Lys-4' (H3K4me3) on genes involved in stem cell pluripotency; this function is synergistic with CXXC1 indicative for an involvement of a SET1 complex (By similarity)

The "RTF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTF2 | RTKN | RTKN2 | RTL1 | RTL10 | RTL3 | RTL4 | RTL5 | RTL6 | RTL8A | RTL8B | RTL8C | RTL9 | RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT